NasdaqGS:STOKBiotechs
Does Stoke Therapeutics’ New Genetic Medicine CSO Hire Reframe Its R&D Ambitions for STOK?
Earlier this month, Stoke Therapeutics appointed Thomas McCauley, Ph.D., as Chief Scientific Officer, adding more than 25 years of R&D and rare disease drug development leadership to its senior team.
His background in advancing genetic and RNA-based medicines, including experience with mRNA technologies and antisense platforms, could be particularly relevant to Stoke’s antisense oligonucleotide programs targeting severe genetic diseases.
Next, we’ll examine how bringing in a Chief Scientific...